Literature DB >> 18840819

Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis.

Bahi Takkouche1, Carlos Regueira-Méndez, Mahyar Etminan.   

Abstract

BACKGROUND: Breast cancer is one of the leading causes of mortality among women. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk for breast cancer, but results from these studies of the association have been inconsistent.
METHODS: Studies that examined the association between risk of breast cancer and use of NSAIDs, including aspirin and ibuprofen, that were published between January 1, 1966, and July 1, 2008, were identified using Medline, EMBASE, and other databases. We performed meta-analysis by pooling studies according to the inverse of their variances and performed separate analyses of studies pooled according to aspirin use and ibuprofen use. We evaluated publication bias and study quality.
RESULTS: A total of 38 studies (16 case-control studies, 18 cohort studies, 3 case-control studies nested in well-defined cohorts, and 1 clinical trial) that included 2 788 715 subjects were identified. The results of these studies suggest that overall, NSAID use was associated with reduced risk for breast cancer (relative risk [RR] = 0.88, 95% confidence interval [CI] = 0.84 to 0.93). Specific analyses for aspirin (RR = 0.87, 95% CI = 0.82 to 0.92) and ibuprofen (RR = 0.79, 95% CI = 0.64 to 0.97) yielded similar results.
CONCLUSIONS: This meta-analysis provides evidence that NSAID use is associated with reduced risk for breast cancer. Future research should include careful evaluation of the biologic mechanisms involved in the relationship between NSAIDs and breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840819     DOI: 10.1093/jnci/djn324

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  102 in total

1.  Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; David S Goerlitz; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2011-04-23       Impact factor: 2.506

2.  Exposure to oral bisphosphonates and risk of cancer.

Authors:  Chris R Cardwell; Christian C Abnet; Philip Veal; Carmel M Hughes; Marie M Cantwell; Liam J Murray
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

3.  Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.

Authors:  E H Allott; C-K Tse; A F Olshan; L A Carey; P G Moorman; M A Troester
Journal:  Breast Cancer Res Treat       Date:  2014-08-24       Impact factor: 4.872

Review 4.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 5.  Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

Authors:  David G Menter; Richard L Schilsky; Raymond N DuBois
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

6.  Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis.

Authors:  Yanli Li; Theodore M Brasky; Jing Nie; Christine B Ambrosone; Susan E McCann; Peter G Shields; Maurizio Trevisan; Stephen B Edge; Jo L Freudenheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-11-08       Impact factor: 4.254

7.  No effect of aspirin on mammographic density in a randomized controlled clinical trial.

Authors:  Anne McTiernan; C Y Wang; Bess Sorensen; Liren Xiao; Diana S M Buist; Erin J Aiello Bowles; Emily White; Mary Anne Rossing; John Potter; Nicole Urban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

8.  Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

Authors:  L Alexis Hoeferlin; Charles E Chalfant; Margaret A Park
Journal:  J Surg Sci       Date:  2013-12

9.  Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.

Authors:  Patricia A Thompson; Chiu-Hsieh Hsu; Sylvan Green; Alison T Stopeck; Karen Johnson; David S Alberts; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

10.  Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; Kirsten B Moysich; David E Cohn; Emily White
Journal:  Gynecol Oncol       Date:  2012-10-09       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.